Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide (HD1916) vs. Ozempic in Type 2 Diabetes
NCT06161844Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06161844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161844.